|
David Kalergis has extensive experience with the commercialization of university research, especially in the area of pharmaceuticals and biotechnology. As CEO of the Company, Mr. Kalergis has overall responsibility for implementing the Company’s strategy, as established by the Board of Directors, as well as handling day-to-day operational matters. Immediately prior to joining Diffusion Pharmaceuticals, he was director of the University of Virginia’s Gateway initiative, dedicated to linking the research activities of the University with the high technology business community. In 2002, he was awarded the Virginia Piedmont Technology Council’s Navigator award for his leadership and contributions to the technology community and the region’s economic development. From 1991 to 1997, Mr. Kalergis was General Counsel, Director of Business Development and Consultant to Pharmaceutical Research Associates, Inc. (PRA), a contract research firm providing drug-development services to the world-wide pharmaceutical and biotechnology industries. He also served on PRA’s Board of Directors. In these roles he was involved in the business, financial planning, and clinical trials implementation of dozens of pharmaceutical compounds in all stages of development, ranging from pre-clinical through post-marketing. Mr. Kalergis currently serves on a number of Boards of Directors in addition to Diffusion Pharmaceuticals, including the Virginia Biotechnology Association. He is a founding director of publicly-traded Virginia National Bank (Trading Symbol: VABK) and serves on its Audit Committee, and as Chairman of its Community Committee. Mr. Kalergis is a graduate of the Harvard Business School’s Leadership and Strategy in Biotechnology and Pharmaceuticals program. He holds BA, MBA, and JD degrees from the University of Virginia, is a member of the New York and Virginia State Bar Associations, and is the author of The Role of the University in the Commercialization of Biotechnology (1981). | 